Parasite Clearance and Protection from Infection (PCPI) in Cameroon

PHASE3CompletedINTERVENTIONAL
Enrollment

902

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

December 25, 2024

Study Completion Date

March 5, 2025

Conditions
Malaria
Interventions
DRUG

SP (Macleods Pharmaceuticals Ltd)

Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine

DRUG

SPAQ (Guilin Pharmaceuticals)

Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.

DRUG

AS (Guilin Pharmaceuticals)

Children will receive 4 mg/kg/day for 7 days

Trial Locations (1)

Unknown

Malantouen District Hospital Catchment Area, Magba

All Listed Sponsors
lead

London School of Hygiene and Tropical Medicine

OTHER

NCT06173206 - Parasite Clearance and Protection from Infection (PCPI) in Cameroon | Biotech Hunter | Biotech Hunter